Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Cardiotoxicity 2Sezary Syndrome 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1PRETEXT I Hepatoblastoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Intraocular Lymphoma 1Inflammatory Breast Neoplasms 1Immunoblastic Lymphadenopathy 1Ganglioneuroblastoma 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Breast Neoplasms 1Blast Crisis 1

Interventions

dinutuximab 4sargramostim 3Topotecan 3Cyclophosphamide 3Colony-Stimulating Factors 3Vincristine 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Radiation 2Platinum 2Melphalan 2Magnetic Resonance Spectroscopy 2Isotretinoin 2Irinotecan 2Etoposide 2Doxorubicin 2Cisplatin 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2temsirolimus 1iberdomide 1Transurethral Resection of Bladder 1Specimen Handling 1Sirolimus 1Razoxane 1Radiotherapy 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ganglioneuroblastoma × Razoxane × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡